Precision Medicine

Awarded in 2018, the DoD-funded TRACK-TBI Precision Medicine project will utilize the rich TRACK-TBI dataset to validate biomarkers of diffuse axonal injury (DAI), microvascular injury (MVI), and neuro-inflammation using advanced blood-based assay platforms and MRI sequences. The project will validate early and ultra-early blood-based and imaging biomarkers of DAI, MVI, and neuro-inflammation and will conduct a multicenter, double-blind, placebo-controlled exploratory clinical trial comparing the impact of cyclosporine A on blood-based and imaging biomarkers of DAI and neuro-inflammation in moderate/severe TBI patients. TRACK-TBI Precision Medicine is a 3-year project.